Cellebrite DI (NASDAQ:CLBT) Given “Buy” Rating at Needham & Company LLC

Needham & Company LLC reissued their buy rating on shares of Cellebrite DI (NASDAQ:CLBT) in a research note issued to investors on Wednesday,Benzinga reports. They currently have a $28.00 price target on the stock.

Several other equities research analysts also recently weighed in on CLBT. JPMorgan Chase & Co. upped their target price on shares of Cellebrite DI from $24.00 to $28.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 11th. Lake Street Capital upped their price objective on Cellebrite DI from $17.00 to $26.00 and gave the stock a “buy” rating in a research report on Friday, February 14th. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $23.43.

Cellebrite DI Trading Up 3.0 %

Shares of NASDAQ CLBT opened at $19.83 on Wednesday. The stock has a market capitalization of $4.75 billion, a PE ratio of -14.27, a PEG ratio of 4.27 and a beta of 1.52. Cellebrite DI has a twelve month low of $10.25 and a twelve month high of $26.30. The stock has a fifty day simple moving average of $20.62 and a 200-day simple moving average of $19.94.

Cellebrite DI (NASDAQ:CLBT) last released its earnings results on Thursday, February 13th. The company reported $0.07 earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.03). Cellebrite DI had a negative net margin of 70.54% and a positive return on equity of 58.70%. On average, equities analysts predict that Cellebrite DI will post 0.3 earnings per share for the current year.

Hedge Funds Weigh In On Cellebrite DI

Several large investors have recently bought and sold shares of the business. Juncture Wealth Strategies LLC boosted its position in shares of Cellebrite DI by 0.8% during the 4th quarter. Juncture Wealth Strategies LLC now owns 60,003 shares of the company’s stock worth $1,322,000 after acquiring an additional 505 shares in the last quarter. Bosun Asset Management LLC boosted its holdings in Cellebrite DI by 1.4% in the fourth quarter. Bosun Asset Management LLC now owns 43,307 shares of the company’s stock valued at $954,000 after purchasing an additional 584 shares in the last quarter. TD Waterhouse Canada Inc. boosted its holdings in Cellebrite DI by 1.8% in the fourth quarter. TD Waterhouse Canada Inc. now owns 47,497 shares of the company’s stock valued at $1,046,000 after purchasing an additional 859 shares in the last quarter. Strategic Advisors LLC increased its stake in Cellebrite DI by 3.4% in the fourth quarter. Strategic Advisors LLC now owns 29,082 shares of the company’s stock valued at $641,000 after purchasing an additional 950 shares during the last quarter. Finally, Steward Partners Investment Advisory LLC raised its holdings in Cellebrite DI by 12.1% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 13,590 shares of the company’s stock worth $299,000 after purchasing an additional 1,463 shares in the last quarter. Hedge funds and other institutional investors own 45.88% of the company’s stock.

Cellebrite DI Company Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.